Amyloid-β, p-tau and reactive microglia are pathological correlates of MRI cortical atrophy in Alzheimer's disease

被引:15
|
作者
Frigerio, Irene [1 ]
Boon, Baayla D. C. [2 ]
Lin, Chen-Pei [1 ]
Galis-de Graaf, Yvon [1 ]
Bol, John [1 ]
Preziosa, Paolo [3 ,4 ]
Twisk, Jos [5 ]
Barkhof, Frederik [6 ,7 ]
Hoozemans, Jeroen J. M. [2 ]
Bouwman, Femke H. [8 ]
Rozemuller, Annemieke J. M. [2 ]
van de Berg, Wilma D. J. [1 ]
Jonkman, Laura E. [1 ]
机构
[1] Vrije Univ Amsterdam, Dept Anat & Neurosci, Amsterdam UMC, Locat VUmc,Amsterdam Neurosci,Sect Clin Neuroanat, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands
[2] Amsterdam UMC, Locat VUmc, Amsterdam Neurosci, Dept Pathol, NL-1081 HV Amsterdam, Netherlands
[3] IRCCS San Raffaele Sci Inst, Neuroimaging Res Unit, Div Neurosci, I-20132 Milan, Italy
[4] IRCCS San Raffaele Sci Inst, Neurol Unit, I-20132 Milan, Italy
[5] Vrije Univ Amsterdam, Dept Epidemiol & Biostat, NL-1081 HV Amsterdam, Netherlands
[6] Amsterdam UMC, Amsterdam Neurosci, Dept Radiol & Nucl Med, Locat VUmc, NL-1081 HV Amsterdam, Netherlands
[7] UCL, Inst Neurol & Healthcare Engn, London WC1E, England
[8] Alzheimer Ctr Amsterdam, Amsterdam Neurosci, Amsterdam UMC, Alzheimer Centrum Amsterdam,Locat VUmc,Dept Neuro, NL-1081 HV Amsterdam, Netherlands
关键词
Alzheimer's disease; cortical thickness; neuropathology; MRI; atypical Alzheimer's disease; NEUROPATHOLOGIC ASSESSMENT; DEFINED SUBTYPES; PET PATTERNS; IN-VIVO; BRAIN; GRAY; INFLAMMATION; ASSOCIATION;
D O I
10.1093/braincomms/fcab281
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Frigerio et al. report that in Alzheimer's disease, amyloid-beta, phosphorylated-tau and reactive microglia load measured with immunohistochemistry, are important correlates of MRI cortical atrophy, acquired both ante-mortem in vivo and post-mortem in situ. In summary, distinct histopathological markers differently correlate with cortical atrophy, highlighting their different roles in the neurodegeneration process. Alzheimer's disease is characterized by cortical atrophy on MRI and abnormal depositions of amyloid-beta, phosphorylated-tau and inflammation pathologically. However, the relative contribution of these pathological hallmarks to cortical atrophy, a widely used MRI biomarker in Alzheimer's disease, is yet to be defined. Therefore, the aim of this study was to identify the histopathological correlates of MRI cortical atrophy in Alzheimer's disease donors, and its typical amnestic and atypical non-amnestic phenotypes. Nineteen Alzheimer's disease (of which 10 typical and 9 atypical) and 10 non-neurological control brain donors underwent post-mortem in situ 3T 3D-T1, from which cortical thickness was calculated with Freesurfer. Upon subsequent autopsy, 12 cortical brain regions from the right hemisphere and 9 from the left hemisphere were dissected and immunostained for amyloid-beta, phosphorylated-tau and reactive microglia, and percentage area load was calculated for each marker using ImageJ. In addition, post-mortem MRI was compared to ante-mortem MRI of the same Alzheimer's disease donors when available. MRI-pathology associations were assessed using linear mixed models. Higher amyloid-beta load weakly correlated with higher cortical thickness globally (r = 0.22, P = 0.022). Phosphorylated-tau strongly correlated with cortical atrophy in temporal and frontal regions (-0.76 < r < -1.00, all P < 0.05). Reactive microglia load strongly correlated with cortical atrophy in the parietal region (r = -0.94, P < 0.001). Moreover, post-mortem MRI scans showed high concordance with ante-mortem scans acquired <1 year before death. In conclusion, distinct histopathological markers differently correlated with cortical atrophy, highlighting their different roles in the neurodegenerative process, and therefore contributing to the understanding of the pathological underpinnings of MRI atrophic patterns in Alzheimer's disease. In our cohort, no or only subtle differences were found in MRI-pathology associations in Alzheimer's disease phenotypes, indicating that the histopathological correlates of cortical atrophy in typical and atypical phenotypes might be similar. Moreover, we show that post-mortem in situ MRI can be used as proxy for ante-mortem in vivo MRI.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Concomitant LATE-NC in Alzheimer's disease is not associated with increased tau or amyloid-β pathological burden
    McAleese, K. E.
    Walker, L.
    Erskine, D.
    Johnson, M.
    Koss, D.
    Thomas, A. J.
    Attems, J.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2020, 46 (07) : 722 - 734
  • [32] Multiple interconnected pathological factors (copper, amyloid-β, and reactive oxygen species) in Alzheimer's disease
    Lim, Mi Hee
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [33] Visual cognition in non-amnestic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy
    Putcha, Deepti
    Brickhouse, Michael
    Touroutoglou, Alexandra
    Collins, Jessica A.
    Quimby, Megan
    Wong, Bonnie
    Eldaief, Mark
    Schultz, Aaron
    El Fakhri, Georges
    Johnson, Keith
    Dickerson, Bradford C.
    McGinnis, Scott M.
    NEUROIMAGE-CLINICAL, 2019, 23
  • [34] Plasma p-tau immunoassays in clinical research for Alzheimer's disease
    Teunissen, Charlotte E.
    Kolster, Rachel
    Triana-Baltzer, Gallen
    Janelidze, Shorena
    Zetterberg, Henrik
    Kolb, Hartmuth C.
    ALZHEIMERS & DEMENTIA, 2025, 21 (01)
  • [35] Cerebral amyloid-β load is associated with neurodegeneration and gliosis: Mediation by p-tau and interactions with risk factors early in the Alzheimer's continuum
    Salvado, Gemma
    Mila-Aloma, Marta
    Shekari, Mahnaz
    Minguillon, Carolina
    Fauria, Karine
    Ninerola-Baizan, Aida
    Perissinotti, Andres
    Kollmorgen, Gwendlyn
    Buckley, Christopher
    Farrar, Gill
    Zetterberg, Henrik
    Blennow, Kaj
    Suarez-Calvet, Marc
    Molinuevo, Jose Luis
    Gispert, Juan Domingo
    ALZHEIMERS & DEMENTIA, 2021, 17 (05) : 788 - 800
  • [36] Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers
    Ossenkoppele, Rik
    Reimand, Juhan
    Smith, Ruben
    Leuzy, Antoine
    Strandberg, Olof
    Palmqvist, Sebastian
    Stomrud, Erik
    Zetterberg, Henrik
    Scheltens, Philip
    Dage, Jeffrey L.
    Bouwman, Femke
    Blennow, Kaj
    Mattsson-Carlgren, Niklas
    Janelidze, Shorena
    Hansson, Oskar
    EMBO MOLECULAR MEDICINE, 2021, 13 (08)
  • [37] Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau
    Janelidze, Shorena
    Palmqvist, Sebastian
    Leuzy, Antoine
    Stomrud, Erik
    Verberk, Inge M. W.
    Zetterberg, Henrik
    Ashton, Nicholas J.
    Pesini, Pedro
    Sarasa, Leticia
    Allue, Jose Antonio
    Teunissen, Charlotte E.
    Dage, Jeffrey L.
    Blennow, Kaj
    Mattsson-Carlgren, Niklas
    Hansson, Oskar
    ALZHEIMERS & DEMENTIA, 2022, 18 (02) : 283 - 293
  • [38] New Treatment for Alzheimer's Disease, Kamikihito, Reverses Amyloid-β-Induced Progression of Tau Phosphorylation and Axonal Atrophy
    Watari, Hidetoshi
    Shimada, Yutaka
    Tohda, Chihiro
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 2014
  • [39] PET Imaging of Tau Pathology and Amyloid-β, and MRI for Alzheimer's Disease Feature Fusion and Multimodal Classification
    Shojaie, Mehdi
    Tabarestani, Solale
    Cabrerizo, Mercedes
    DeKosky, Steven T.
    Vaillancourt, David E.
    Loewenstein, David
    Duara, Ranjan
    Adjouadi, Malek
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 84 (04) : 1497 - 1514
  • [40] Pyroglutamylated amyloid-β is associated with hyperphosphorylated tau and severity of Alzheimer's disease
    Mandler, Markus
    Walker, Lauren
    Santic, Radmila
    Hanson, Peter
    Upadhaya, Ajeet Rijal
    Colloby, Sean J.
    Morris, Christopher M.
    Thal, Dietmar R.
    Thomas, Alan J.
    Schneeberger, Achim
    Attems, Johannes
    ACTA NEUROPATHOLOGICA, 2014, 128 (01) : 67 - 79